Cetuximab sensitizes CRC cells to CPT-11—a chemotherapy drug—by suppressing HSP27 activity by targeting the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. The gene discussed is HSPB2; the disease is colorectal carcinoma.